Personalized medicine in breast cancer: A systematic review

Journal of Breast Cancer

Volumn 15, Issue 3, 2012, Pages 265-272

  Cho, Sang Hoon ^a   Jeon, Jongsu ^a   Kim, Seung Il ^b  

^a Soongsil University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Biomarker discovery; Breast neoplasms; Individualized medicine; Predictive biomarker; Prognostic biomarker

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LAPATINIB; LETROZOLE; MOLECULAR MARKER; PERTUZUMAB; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; DEVICES; DIAGNOSTIC TEST; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG INDUCED DISEASE; GENE EXPRESSION PROFILING; GENETIC RISK; GENOME ANALYSIS; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; METABOLOMICS; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; PROTEOMICS; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TRANSCRIPTOMICS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84867668788     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2012.15.3.265     Document Type: Review

References (81)

1. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmaco-genetics. Trends Mol Med 2001;7:201-4.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
3. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
4. President's Council of Advisors on Science and Technolgy. Priorities for Personalized Medicine. Washington, DC: President's Council of Advisors on Science and Technolgy; 2008.
5. Pfizer. Think Science Now Perspective. Approaches to Cancer Care: the Promise of Personalized Medicine. New York: Pfizer; 2010.
6. Genetics home reference: Glossary. U.S. National Institutes of Health, U.S. National Library of Medicine. http://ghr.nlm.nih.gov/glossary=person alizedmedicine. Accessed July 1st, 2012.
7. Meadows M. Genomics and personalized medicine. FDA Consum 2005;39:12-7.
8. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
9. Micheel C, Ball J; Institute of Medicine (U.S.). Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington, DC: National Academies Press; 2010.
10. NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991;265:391-5.
11. Clark GM, Zborowski DM, Culbertson JL, Whitehead M, Savoie M, Seymour L, et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol 2006;1:837-46.
12. Saez RA, McGuire WL, Clark GM. Prognostic factors in breast cancer. Semin Surg Oncol 1989;5:102-10.
13. Nemoto T, Natarajan N, Bedwani R, Vana J, Murphy GP. Breast cancer in the medial half. Results of 1978 National Survey of the American College of Surgeons. Cancer 1983;51:1333-8.
14. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983; 52:1551-7.
15. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
16. Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/ T2N0M0 patients with long-term follow-up. J Clin Oncol 1993;11: 2090-100.
17. Carstens PH, Greenberg RA, Francis D, Lyon H. Tubular carcinoma of the breast. A long term follow-up. Histopathology 1985;9:271-80.
18. Clayton F. Pure mucinous carcinomas of breast: morphologic features and prognostic correlates. Hum Pathol 1986;17:34-8.
19. Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977; 40:1365-85.
20. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989;64:1914-21.
21. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989;7:1239-51.
22. Neville AM, Bettelheim R, Gelber RD, Säve-Söderbergh J, Davis BW, Reed R, et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:696-705.
23. Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991;63:447-50.
24. Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SA, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-7.
25. Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991;51:556-67.
26. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991;51:944-8.
27. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994; 12:888-94.
28. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 1994:35-42.
29. Daly MB, Clark GM, McGuire WL. Breast cancer prognosis in a mixed Caucasian-Hispanic population. J Natl Cancer Inst 1985;74:753-7.
30. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994;86:705-12.
31. Pierce L, Fowble B, Solin LJ, Schultz DJ, Rosser C, Goodman RL. Conservative surgery and radiation therapy in black women with early stage breast cancer. Patterns of failure and analysis of outcome. Cancer 1992; 69:2831-41.
32. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008;44:946-53.
33. Bentzen SM, Buffa FM, Wilson GD. Multiple biomarker tissue microarrays: bioinformatics and practical approaches. Cancer Metastasis Rev 2008;27:481-94.
34. Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol 2008;1:406-12.
35. Phan JH, Moffitt RA, Stokes TH, Liu J, Young AN, Nie S, et al. Convergence of biomarkers, bioinformatics and nanotechnology for individu-alized cancer treatment. Trends Biotechnol 2009;27:350-8.
36. Drug information: drugs approved for different types of cancer. National Cancer Institute. http://www.cancer.gov/cancertopics/druginfo/drugpage-index. Accessed July 1st, 2012.
37. Drug information: drugs approved for breast cancer. National Cancer Institute. http://www.cancer.gov/cancertopics/druginfo/breastcancer. Accessed July 1st, 2012.
38. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005;103:2241-51.
39. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
40. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
41. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
42. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
43. Jones DS, Hofmann L, Quinn S. 21st Century Medicine: A New Model for Medical Education and Practice. Gig Harbor: The Institute for Functional Medicine; 2010. p.23-87.
44. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
45. BRCA1 and BRCA2: cancer risk and genetic testing.National Cancer Institute. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. Accessed July 1st, 2012.
46. Drugs@FDA: FDA approved drug products. U.S. Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed July 1st, 2012.
47. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005;11:313-24.
48. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
49. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164:35-42.
50. MammaPrint Agendia. http://www.agendia.com/pages/mammaprint/21.php. Accessed July 1st, 2012.
51. Personalized Medicine Coalition. The Case for Personalized Medicine. 3rd ed. Washington, DC: Personalized Medicine Coalition; 2011.
52. Catchpoole DR, Kennedy P, Skillicorn DB, Simoff S. The curse of dimensionality: a blessing to personalized medicine. J Clin Oncol 2010;28: e723-4.
53. Cheng F, Cho SH, Lee JK. Multi-gene expression-based statistical approaches to predicting patients' clinical outcomes and responses. Methods Mol Biol 2010;620:471-84.
54. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007; 104:13086-91.
55. Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011;12:137-43.
56. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001;98:10787-92.
57. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
58. Efron B, Tibshirani R, Storey JD, Tusher V. Empirical bayes analysis of a microarray experiment. J Am Stat Assoc 2001;96:1151-60.
59. Dudoit R, Yang YH, Callow MJ, Speed TP. Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments. Stat Sin 2002;12:111-39
60. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
61. Hu J, Wright FA. Assessing differential gene expression with small sample sizes in oligonucleotide arrays using a mean-variance model. Biometrics 2007;63:41-9.
62. Lönnstedt I, Speed T. Replicated microarray data. Stat Sin 2002;12:31-46.
63. Newton MA, Kendziorski CM, Richmond CS, Blattner FR, Tsui KW. On differential variability of expression ratios: improving statistical inference about gene expression changes from microarray data. J Comput Biol 2001;8:37-52.
64. Newton MA, Noueiry A, Sarkar D, Ahlquist P. Detecting differential gene expression with a semiparametric hierarchical mixture method. Biostatistics 2004;5:155-76.
65. Wolfinger RD, Gibson G, Wolfinger ED, Bennett L, Hamadeh H, Bushel P, et al. Assessing gene significance from cDNA microarray expression data via mixed models. J Comput Biol 2001;8:625-37.
66. Wang S, Ethier S. A generalized likelihood ratio test to identify differentially expressed genes from microarray data. Bioinformatics 2004;20: 100-4.
67. Jain N, Thatte J, Braciale T, Ley K, O'Connell M, Lee JK. Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics 2003;19:1945-51.
68. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
69. Brown MP, Grundy WN, Lin D, Cristianini N, Sugnet CW, Furey TS, et al. Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci U S A 2000;97:262-7.
70. Furey TS, Cristianini N, Duffy N, Bednarski DW, Schummer M, Haussler D. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 2000;16:906-14.
71. Mukherjee S, Tamayo P, Slonim D, Verri A, Golub T, Mesirov JP, et al. Support Vector Machine Classication of Microarray Data. Cambridge: Massachusetts Institute of Technology; 1998.
72. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98:11462-7.
73. Nguyen DV, Rocke DM. Tumor classification by partial least squares using microarray gene expression data. Bioinformatics 2002;18:39-50.
74. Nagji AS, Cho SH, Liu Y, Lee JK, Jones DR. Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Mol Cancer Ther 2010;9:2834-43.
75. Culhane AC, Perrière G, Considine EC, Cotter TG, Higgins DG. Between-group analysis of microarray data. Bioinformatics 2002;18:1600-8.
76. Bradley AP. The use of the area under the ROC curve in the evaluation of machine learning algorithms. Pattern Recognit 1997;30:1145-59.
77. Hand DJ. Construction and Assessment of Classification Rules. Chichester: Wiley; 1997.
78. Soukup M, Lee JK. Developing optimal prediction models for cancer classification using gene expression data. J Bioinform Comput Biol 2004;1:681-94.
79. Soukup M, Cho H, Lee JK. Robust classification modeling on microarray data using misclassification penalized posterior. Bioinformatics 2005;21 Suppl 1:i423-30.
80. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points: the challenge of statistical validation. Nat Rev Clin Oncol 2010;7:309-17.
81. DNA sequencing costs: data from the NHGRI large scale genome sequencing program. Wetterstrand KA. http://www.genome.gov/sequencingcosts/. Accessed July 1st, 2012.